Literature DB >> 8985192

Patients infected with the same hepatitis C virus strain display different kinetics of the isolate-specific antibody response.

T Allander1, A Beyene, S H Jacobson, L Grillner, M A Persson.   

Abstract

The antibody response to the hypervariable region of the E2 protein (HVR1) of hepatitis C virus (HCV) was studied in 5 patients who were infected by a common virus strain during an outbreak in a hemodialysis unit. Two patients resolved the infection, while 3 developed chronic HCV infection. For studying the antibody response to HVR1 during the early phase of infection, a Western blot assay using recombinant phage displaying HVR1 was developed. The 2 patients with resolving infection had a more rapid antibody response to HVR1 than did the patients developing chronic infection. Anti-HVR1 antibodies were repeatedly absent in 1 of the chronically infected patients. Antibodies to recombinant E2 protein occurred later than the anti-HVR1 antibodies and did not correlate with resolution of the infection. Thus, the present results suggest that early appearance of antibodies to the HVR1 may predict clearance of HCV infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8985192     DOI: 10.1093/infdis/175.1.26

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes.

Authors:  H C Zhou; D Z Xu; X P Wang; J X Zhang; Y Huang; Y P Yan; Y Zhu; B Q Jin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort.

Authors:  J McAllister; C Casino; F Davidson; J Power; E Lawlor; P L Yap; P Simmonds; D B Smith
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

3.  Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.

Authors:  Jean-Christophe Meunier; Ronald E Engle; Kristina Faulk; Ming Zhao; Birke Bartosch; Harvey Alter; Suzanne U Emerson; Francois-Loic Cosset; Robert H Purcell; Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-14       Impact factor: 11.205

4.  In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells.

Authors:  Akito Sakai; Shingo Takikawa; Robert Thimme; Jean-Christophe Meunier; Hans Christian Spangenberg; Sugantha Govindarajan; Patrizia Farci; Suzanne U Emerson; Francis V Chisari; Robert H Purcell; Jens Bukh
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

5.  Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees.

Authors:  X Forns; R Thimme; S Govindarajan; S U Emerson; R H Purcell; F V Chisari; J Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

6.  Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus.

Authors:  M E Major; K Mihalik; J Fernandez; J Seidman; D Kleiner; A A Kolykhalov; C M Rice; S M Feinstone
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

7.  Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees.

Authors:  S E Bassett; D L Thomas; K M Brasky; R E Lanford
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.

Authors:  Birke Bartosch; Jens Bukh; Jean-Christophe Meunier; Christelle Granier; Ronald E Engle; William C Blackwelder; Suzanne U Emerson; François-Loïc Cosset; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-14       Impact factor: 11.205

Review 9.  The past, present and future of neutralizing antibodies for hepatitis C virus.

Authors:  Jonathan K Ball; Alexander W Tarr; Jane A McKeating
Journal:  Antiviral Res       Date:  2014-02-26       Impact factor: 5.970

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.